Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 3:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2905–2928 of 85,971 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Hepatocellular Carcinoma, Liver Cancer
Interventions: bavituximab (0.3 mg/kg) and sorafenib, bavituximab (1.0 mg/kg ) and sorafenib, bavituximab (3.0 mg/kg) and sorafenib; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Malignant Pleural Effusion
Interventions: Aspira Catheter, Ultrasound; Device · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Head and Neck Cancer
Interventions: carboplatin, fluorouracil, hydroxyurea, paclitaxel, conventional surgery, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 15 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 4
States / cities: Chicago, Illinois

Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer
Interventions: Lutetium Lu 177-PSMA-617, Pembrolizumab; Drug · Biological
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Advanced Cancer
Interventions: Resilient Living Program; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: Azithromycin Tablets 600 mg, Zithromax® Tablets 600 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Congenital Urological Abnormalities
Interventions: mycophenolate mofetil; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 3 Years to 16 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 3
States / cities: New Brunswick, New Jersey • New Hyde Park, New York • New York, New York

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Primaquine, Clindamycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 3 more

Conditions: Sleep Apnea, Pre-diabetes
Interventions: Continuous positive airway pressure, Niacin; Device · Other
Lead sponsor: University of Chicago; Other
Eligibility: 20 Years to 69 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Serious Mental Illness, Psychosocial Rehabilitation
Interventions: HOPES Program ("Helping Older People Experience Success"); Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Glencliff, New Hampshire

Conditions: Opioid-use Disorder
Interventions: XR-B (SUBLOCADETM), XR-NTX; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: New Haven, Connecticut • Baltimore, Maryland • Hanover, New Hampshire + 3 more

Conditions: Abdominoplasty, Bilateral Breast Reduction, Bilateral Breast Lift, Bilateral Brachioplasty, Bilateral Lateral Thigh and Buttocks Lift
Interventions: E-Z Clean ACE Blade; Device
Lead sponsor: Megadyne Medical Products Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Twin Falls, Idaho • Fort Wayne, Indiana • Winston-Salem, North Carolina

Conditions: Workplace Culture, Help-Seeking Behavior, Social Stigma, Education, Medical, Continuing
Interventions: Popular-Opinion Leader-led encouragement during training meetings and informal conversation; Other
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 493 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Mantle Cell Lymphoma
Interventions: Rituximab, bortezomib, Cladribine; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 2
States / cities: Hershey, Pennsylvania

Conditions: DeQuervain's Tenosynovitis
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Solid Tumors
Interventions: AZD2281, Cisplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2023
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)
Interventions: Nanvuranlat, Physician's Best Choice; Drug · Other
Lead sponsor: J-Pharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 18
States / cities: Duarte, California • Orange, California • Santa Monica, California + 15 more

Conditions: Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer
Interventions: MEK162, MEK inhibitor; oral, Physician's choice chemotherapy; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 77
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 37 more

Conditions: Obesity, Weight Gain, Psychotropic Induced Weight Gain
Interventions: Metformin; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 10 Years to 17 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Oropharyngeal Cancer, Squamous Cell Carcinoma, Human Papilloma Virus
Interventions: Radiation Therapy (IMRT or IMPT); Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Leiomyosarcoma
Interventions: Lurbinectedin, Doxorubicin; Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years and older
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 24
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 18 more

Conditions: Post Traumatic Stress Disorder
Interventions: Narrative Exposure Therapy; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Cognitive Impairment, Dementia, Memory Loss
Interventions: Home Alone; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 55 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Tobacco Use
Interventions: Product A, Product B, Product C, Product D, Product E, Product F; Other
Lead sponsor: Altria Client Services LLC; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 3
States / cities: Lexington, Kentucky • Springfield, Missouri • Knoxville, Tennessee

Search by objective public record fields.

Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer

Management of Malignant Pleural Effusions Using an Indwelling Tunneled Pleural Catheter and Non-Vacuum Collection System

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Resilient Living Program for Patients With Advanced Cancer and Their Caregivers

Fed Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mg

Pilot Study of Mycophenolate Mofetil in Congenital Uropathies

The Safety and Efficacy of Clindamycin and Primaquine in the Treatment of Mild - Moderate Pneumocystis Carinii Pneumonia in Patients With AIDS

Mechanisms of Prediabetic States in Sleep Apnea

Using The HOPES Program in Transition Care

Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults

Megadyne Ace Incision/Dissection Study

Evaluating a Physician Opinion Leader Intervention to Increase Utilization of Coaching/Therapy During Residency

Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)

A Clinical Trial of Splinting for DeQuervain's Tenosynovitis

Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients

A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

Reducing Antipsychotic-Induced Weight Gain in Children With Metformin

TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

Stress Reduction in Middle Eastern Refugees

Home Alone: An Intervention for People With Cognitive Impairment Who Live Alone

Pharmacokinetic and Subjective Effects of Heated Tobacco Products